奈达铂联合多西他赛治疗老年晚期非小细胞肺癌的疗效评价

Evaluation of the Efficacy of Nedaplatin Combined with Docetaxel in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

目的:分析针对老年晚期非小细胞肺癌患者采取奈达铂联合多西他赛治疗临床效果与价值。方法:选取院内2017年~2019年收治老年晚期非小细胞肺癌患者共计80例,采取区分治疗的方式划分对照组和观察组各40例,对照组采取单一多西他赛治疗,观察组患者采取多西他赛联合奈达铂进行治疗,对比两组患者癌胚抗原值以及临床治疗效果,评价药物临床价值。结果:通过研究对比发现,观察组患者在临床治疗效果方面达到60%,对照组仅为30%,差异显著(P<0.05);对比两组患者的癌胚抗原值,观察组同样低于对照组,差异显著(P<0.05);对比两组患者临床治疗的并发症发病情况,观察组优于对照组(P<0.05)。结论:奈达铂联合多西他赛进行老年晚期非小细胞肺癌患者具有很好的适应性,能够改善患者预后水平,快速降低癌胚抗原,提升治疗效果,具有推广应用的价值。

Objective:To analyze the clinical effect and value of nedaplatin combined with docetaxel in elderly patients with advanced non-small cell lung cancer.Methods:A total of 80 elderly patients with advanced non-small cell lung cancer treated in a hospital from 2017 to 2019 were selected and divided into the control group and the observation group according to the different treatment methods,with 40 cases in each group.The control group was treated with single docetaxel and the observation group patients was treated with docetaxel combined with nedaplatin,then the carcinoembryonic antigen value and clinical treatment effect of the two groups of patients were compared to evaluate the clinical value of the drugs.Results:Through research and comparison,it was found that the clinical treatment effect was 60%in the observation group and only 30%in the control group,and the difference was significant(P<0.05).The carcinoembryonic antigen value in the observation group was lower than that in the control group,with a significant difference(P<0.05).Comparing the incidence of complications in clinical treatment between the two groups,the observation group was better than the control group(P<0.05).Conclusion:Nedaplatin combined with docetaxel has good adaptability in elderly patients with advanced non-small cell lung cancer,which can improve the prognosis level of patients,rapidly reduce the carcinoembryonic antigen,and improve the treatment effect,and is worthy of promotion and application.